Your browser doesn't support javascript.
loading
Early Versus Late Administration of Long-Acting Insulin in Adult Diabetic Ketoacidosis.
Do, Michael M; Fleury, Jacklyn A; Morgan, Grant P; Hall Zimmerman, Lisa; Hanni, Claudia M; Sulaiman, Hiba; Lutz, Mark F.
Affiliation
  • Do MM; Department of Pharmacy Services, Corewell Health William Beaumont University Hospital, Royal Oak, MI, USA.
  • Fleury JA; Wayne State University Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, USA.
  • Morgan GP; Department of Pharmacy Services, Corewell Health William Beaumont University Hospital, Royal Oak, MI, USA.
  • Hall Zimmerman L; Department of Pharmacy Services, Corewell Health William Beaumont University Hospital, Royal Oak, MI, USA.
  • Hanni CM; Department of Pharmacy Services, Corewell Health William Beaumont University Hospital, Royal Oak, MI, USA.
  • Sulaiman H; Department of Pharmacy Services, Corewell Health William Beaumont University Hospital, Royal Oak, MI, USA.
  • Lutz MF; Department of Pharmacy Services, Corewell Health William Beaumont University Hospital, Royal Oak, MI, USA.
Ann Pharmacother ; : 10600280241278371, 2024 Sep 09.
Article in En | MEDLINE | ID: mdl-39250171
ABSTRACT

BACKGROUND:

Evidence is inconclusive if early administration of subcutaneous (SQ) long-acting insulin (LAI) in management of diabetic ketoacidosis (DKA) improves outcomes.

OBJECTIVE:

This study compares early versus late administration of SQ LAI in time to DKA resolution.

METHODS:

This single-center, retrospective study included patients with DKA who received ≥12 hours of continuous intravenous insulin (CIVI) with LAI overlap. Patients were compared based on LAI administration time to CIVI initiation Early (<12 hours) versus Late (≥12 hours). The DKA resolution is defined as blood glucose < 200 mg/dL and 2 of the following anion gap < 12 mEq/L, pH > 7.35, or serum carbon dioxide >15 mEq/L. Outcomes included time to DKA resolution, length of stay (LOS), CIVI duration, and adverse events.

RESULTS:

A total of 27 patients were included in each group. Baseline characteristics were similar between both groups. There was no difference in time to DKA resolution, Early = 17.6 (13.9-26.8) hours versus Late = 19.2 (17.1-32.1) hours, P = 0.16. The Early group had shorter CIVI duration (Early = 19.5 ± 10.3 hours vs Late = 25.6 ± 8.4 hours, P = 0.02) and received less intravenous (IV) fluids in the first 36 hours (Early = 4.04 ± 2.12 L vs Late = 5.85 ± 2.24 L, P = 0.004). No differences were identified with adverse events, including hypoglycemia, or LOS. CONCLUSION AND RELEVANCE Administration of SQ LAI < 12 hours did not decrease time to DKA resolution or LOS. Patients in the Early group had received a lower dose of LAI, shorter duration of CIVI infusion, and required less IV fluids within 36 hours of admission. This study supports the need for further research to determine the potential benefits of administering SQ insulin early in managing DKA.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Ann Pharmacother Journal subject: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2024 Document type: Article Affiliation country: United States Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Ann Pharmacother Journal subject: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2024 Document type: Article Affiliation country: United States Country of publication: United States